MHRA clarifies UK position on microbiome-based medicines
The MHRA has published its position paper clarifying how microbiome-based medicines can be made available for patients in the UK.
Newsletters and Deep Dive digital magazine
The MHRA has published its position paper clarifying how microbiome-based medicines can be made available for patients in the UK.
After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.
Bristol Myers Squibb's CELMoD pipeline has delivered its first approval, for iberdomide, as part of a combination regimen for multiple myeloma.
Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.
ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.
Editor's Picks
Newsletters and Deep Dive
digital magazine